Back to top
more

CONMED (CNMD)

(Delayed Data from NYSE)

$73.22 USD

73.22
410,616

-0.74 (-1.00%)

Updated Aug 30, 2024 04:00 PM ET

After-Market: $73.21 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 26% (185 out of 251)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

Thermo Fisher Acquires GlaxoSmithKline's Drug Production Site

The latest acquisition aligns with Thermo Fisher's (TMO) strategy of enhancing capabilities of its Pharma Services through the right balance of capital investment, and merger and acquisition.

Here's Why You Should Hold on to Tandem (TNDM) Stock for Now

Investor confidence in Tandem Diabetes (TNDM) is still high on several positive factors.

Varian Medical Installs ProBeam at Research Hub in Singapore

Varian Medical's (VAR) APAC revenues grow 7% year over year in the fiscal second quarter.

Here's Why You Should Hold on to ResMed (RMD) Stock for Now

ResMed (RMD) continues to see strong sales from SaaS business as well as new mask products and devices.

Integra LifeSciences Rides on Product Launch, Faces Rivalry

Benefiting from new products and an improved sales force performance, Integra LifeSciences (IART) projects speedy organic growth in the second half of 2019.

STERIS (STE) Q4 Earnings Surpass Estimates, Margins Rise

STERIS (STE) witnesses solid revenue growth across each of its operating segments in the reported quarter.

Medtronic to Acquire Titan Spine for Spine Portfolio Boost

According to Medtronic (MDT), interbody implants material and shape play a vital role in the bone growth process during fusions and presently, titanium interbody devices are rapidly becoming popular.

ABIOMED's Impella 5.0 and LD Receive Expanded FDA Approvals

ABIOMED's (ABMD) FDA-approved Impella 2.5 and Impella CP treat certain advanced heart failure patients.

Abbott Rides on Strong CGM, Poor Rhythm Management Ails

Abbott (ABT) is attracting constant attention with developments in its flagship, sensor-based continuous glucose monitoring (CGM) system called FreeStyle Libre System.

Medtronic's (MDT) EV ICD Pilot Study Results Encourage

The study highlights the benefits of traditional, transvenous ICDs offered by the Medtronic's (MDT) EV ICD system.

Nevro (NVRO) Q1 Loss Wider Than Expected, Revenues Down Y/Y

Nevro's (NVRO) domestic and international revenues fall year over year in Q1.

Here's Why You Should Invest in Illumina (ILMN) Stock Now

Illumina (ILMN) has been gaining investor confidence on robust performance.

National Vision's (EYE) Q1 Earnings Beat, Margins Decline

National Vision's (EYE) consistent strength in comps is owing to higher customer transaction for the past 69 straight quarters.

Syneos' (SYNH) Q1 Earnings Miss Estimates, Revenues In Line

Syneos Health (SYNH) sees strong year-over-year revenue growth across both operating segments ??? Clinical Solutions and Commercial Solutions.

LHC Group (LHCG) Earnings Beat, Revenues Miss Estimates in Q1

LHC Group (LHCG) gains from solid home health services in Q1, raises 2019 view.

BioScrip's Option Care Merger on Track, Q1 Loss Narrows

BioScrip (BIOS) is highly upbeat about the strategic and financial virtues of Option Care consolidation.

Cardinal Health (CAH) Q3 Earnings Top Estimates, Revenues Lag

Cardinal Health (CAH) Q3 results benefit from strong performance by Pharmaceutical segment and higher revenues. However, sluggishness in the Medical segment remains a concern.

Bio-Rad (BIO) Q1 Earnings Beat Estimates, Margins Expand

Bio-Rad (BIO) witnesses revenue growth at the Life Sciences segment in Q1 on strength in cell biology, droplet Digital PCR and other product lines.

Wright Medical (WMGI) Q1 Earnings & Revenues Top Estimates

Wright Medical (WMGI) Q1 results benefit from higher revenues, solid show by Lower as well as Upper Extremities segments and gross margin expansion. However, rising costs remain a woe.

OPKO Health (OPK) Reports Loss in Q1, Misses Revenue Estimates

Lower revenues, weak performing product segment and contraction in gross margin impact OPKO Health's (OPK) Q1 results.

Becton, Dickinson (BDX) Q2 Earnings Beat, Revenues Fall Y/Y

Becton, Dickinson (BDX) gains from BD Medical in fiscal Q2; international revenues down.

Phibro's (PAHC) Q3 Earnings Miss Estimates, Margins Fall

Phibro Animal Health (PAHC) sees year-over-year revenue decline in two core segments ??? Animal Health and Mineral Nutrition.

Haemonetics (HAE) Q4 Earnings Top Mark, Operating Margin Up

A steady momentum in new business wins and consistent geographical expansion drive Haemonetics' (HAE) top-line results

Bruker (BRKR) Q1 Earnings Beat Estimates, Guidance Upbeat

Bruker's (BRKR) current focus on product development through higher R&D investment stokes investors' positive sentiment around the stock.

McKesson (MCK) Q4 Earnings Beat, Revenues Miss Estimates

McKesson's (MCK) Q4 results benefit from higher revenues, gross margin expansion and solid show by U.S. Pharmaceutical and Specialty Solutions.